

Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

CIN: L24230GJ1992PLC017820

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Opp. PCI, Ankleshwar – 393 002, Gujarat, India Tel : (02646) 220774 Fax : (02646) 251291 Web: www.samratpharmachem.com

Corporate Office

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India. Tel : (91-22) 26701050/1/2 Fax : (91-22) 26701053 E: contact@samratpharmachem.in

January 14, 2020

To, Department of Corporate Services, BSE Limited 25th Floor, P J Towers, Dalal Street, <u>Mumbai - 400 001.</u>

Dear Sir,

Sub: Reconciliation of Share Capital Audit f.t.g.e. 31/12/2019

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended December 31, 2019.

[•] Thanking you,

Yours faithfully, For Samrat Pharmachem Limited

Sandeep Prajapati Compliance Officer

Aqueel A. Mulla

B.Com., L.L.M., F.C.S., A.C.I.S. (U.K.)., D.I.T., Ph.D

A. A. MULLA & ASSOCIATES Company Secretaries

Room No.603, A Wing, 6th Floor, Dhamm Seva CHS, Deluxe Building, Opp. Kurla Station East, Mumbai – 400 024. M: 9892237418 Email: aqueelmulla@gmail.com

January 14, 2020

The Board of Directors, M/s. Samrat Pharmachem Limited Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, <u>Gujarat.</u>

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended 31st December, 2019, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

Yours faithfully, For A.A. Mulla & Associates A **Company Secretaries** MUMBAI MEM. No. 297 COP No. 323 Aqueel A Proprietor

UDIN: F002973B000054596

Reconciliation of Share Capital Audit Report

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details				
1.	For Quarter Ended	31 st December, 2019				
2.	ISIN	INE103E01016				
3.	Face Value	Rs. 10				
4.	Name of the Company	Samrat Pharmachem Limited				
5.	Registered Office Address	Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat.				
6.	Correspondence Address	701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058.				
7.	Tel No. & Fax No.	Tel : (022) 26701050 Fax : (022) 26701053				
8.	Email Address Website	contact@samratpharmachem.in www.samratpharmachem.com				
9.	Names of the stock exchanges where the company's securities are listed.	Mumbai				
10.	Issued Capital	No. of shares % of total issued capita				
		30,89,700 100.00 %				
11.	Listed Capital (Exchange Wise) As per company records It is same for all the exchanges	30,89,700 100.00 %				
12.	Held in dematerialized form in CDSL	4,13,340 13.38 %				
13.	Held in dematerialized form in NSDL	23,10,150 74.77 %				
14.	Physical	3,66,210 11.85 %				
15.	Total No. of shares (12+13+14)	30,89,700 100.00 %				
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)	Nil				

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes	
	If not, updated upto which date	Not Applicable	SULLA & ASSOC
			MUMBAI

D

19. Reference of previous quarter with regards to excess de-materialised shares, if any.

-	_

20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter ? If not, reason why ?

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. & Membership	Name	:	Mr. Sandeep Umashankar Prajapti
	No. of the Compliance Officer of the Co.	Tel No.	:	(91) 9867228874
		Fax No.	:	-
		Membership	:	ACS-57823
		No.		
	and a second	Email	:	contact@samratpharmachem.in

23.	Name, Address, Tel No. & Fax No., Regn	Name	:	A. A. Mulla & Associates
	No. of the Certifying CA/CS			Company Secretaries
		Address	:	Room No.603, A Wing, 6th Floor,
				Dhamm Seva CHS, Deluxe Building,
				Opp Kurla Station East,
				Mumbai-400024
		Tel No.	:	(91) 9892237418
		Email	:	aqueelmulla@gmail.com

24.	Appointment of common agency for	Name	:	Link Intime India Pvt Ltd
	share registry work	Address	:	C-101, 247 Park,
				L. B. S. Marg, Vikhroli (West),
				Mumbai – 400 083, Maharashtra.
		Tel No.		(022) 49186000
		Fax No.		(022) 49186060
		Email	:	rnt.helpdesk@linkintime.co.in
		Kind Attn	:	Ms. Shweta Poojari

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

Date : January 14, 2020 Place : Mumbai

Company Secretaries A&AS MUMBAI D MEM. No. 2973 Aqueel A Mulla COP No. 323 Proprietor YSEC C.P. No. 3237 CS No. 2973 UDIN: F002973B000054596

For A. A. Mulla & Associates